EE200200263A - Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid - Google Patents

Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid

Info

Publication number
EE200200263A
EE200200263A EEP200200263A EEP200200263A EE200200263A EE 200200263 A EE200200263 A EE 200200263A EE P200200263 A EEP200200263 A EE P200200263A EE P200200263 A EEP200200263 A EE P200200263A EE 200200263 A EE200200263 A EE 200200263A
Authority
EE
Estonia
Prior art keywords
telomers
therapeutic combinations
structure fixing
quadruplex structure
fixing compounds
Prior art date
Application number
EEP200200263A
Other languages
English (en)
Estonian (et)
Inventor
Mailliet Patrick
Riou Jean-Fran�ois
Mergny Jean-Louis
Laoui Abdelazize
Lavelle Fran�ois
Petitgenet Odile
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of EE200200263A publication Critical patent/EE200200263A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200200263A 1999-11-29 2000-11-27 Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid EE200200263A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (fr) 1999-11-29 1999-11-29 Derives chimiques et leur application comme agent antitelomerase
FR0010561 2000-08-11
PCT/FR2000/003310 WO2001040218A1 (fr) 1999-11-29 2000-11-27 Derives arylamines et leur application comme agent antitelomerase

Publications (1)

Publication Number Publication Date
EE200200263A true EE200200263A (et) 2003-06-16

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200263A EE200200263A (et) 1999-11-29 2000-11-27 Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid

Country Status (27)

Country Link
EP (1) EP1244650B1 (sh)
JP (1) JP2003515604A (sh)
KR (1) KR20020058043A (sh)
CN (1) CN1402722A (sh)
AT (1) ATE243692T1 (sh)
AU (1) AU2179001A (sh)
BG (1) BG106753A (sh)
BR (1) BR0015992A (sh)
CA (1) CA2392507A1 (sh)
CO (1) CO5251431A1 (sh)
CZ (1) CZ20021849A3 (sh)
DE (1) DE60003583T2 (sh)
DK (1) DK1244650T3 (sh)
EA (1) EA200200616A1 (sh)
EE (1) EE200200263A (sh)
ES (1) ES2202206T3 (sh)
HU (1) HUP0204429A2 (sh)
IL (1) IL149402A0 (sh)
MX (1) MXPA02005276A (sh)
NO (1) NO20022528L (sh)
PE (1) PE20010912A1 (sh)
PL (1) PL355667A1 (sh)
PT (1) PT1244650E (sh)
SK (1) SK7402002A3 (sh)
UY (1) UY26456A1 (sh)
WO (1) WO2001040218A1 (sh)
YU (1) YU38102A (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
EP1294709A2 (en) 2000-01-28 2003-03-26 AstraZeneca AB Quinoline derivatives and their use as aurora 2 kinase inhibitors
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
WO2002012194A1 (fr) * 2000-08-08 2002-02-14 Aventis Pharma S.A. Derives de phenanthridine et leur application comme agents antitelomerases
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
AU2002314252A1 (en) 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1546129A1 (en) * 2002-09-10 2005-06-29 Pharmacia Italia S.p.A. Substituted pyridine derivatives as antitumor agent
AU2003275726A1 (en) * 2002-10-24 2004-05-13 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
CA2546727C (en) * 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
US9127164B2 (en) 2005-10-28 2015-09-08 Almac Sciences (Scotland) Limited Fluorescent dyes and uses thereof
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (ko) * 2006-07-07 2007-10-04 김현기 트리아진 유도체 화합물 및 이를 포함하는 암 치료용조성물
JP2009545592A (ja) * 2006-07-31 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド コード化小分子ライブラリーからのオーロラキナーゼ阻害剤
JP5325517B2 (ja) * 2007-10-12 2013-10-23 住友化学株式会社 ジベンゾオキセピン化合物の精製方法
JP2009102249A (ja) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd ジベンゾオキセピン化合物の結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
EP1053237B1 (en) * 1998-02-04 2003-07-02 The Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
DE19812879A1 (de) * 1998-03-24 1999-09-30 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine

Also Published As

Publication number Publication date
KR20020058043A (ko) 2002-07-12
CN1402722A (zh) 2003-03-12
NO20022528D0 (no) 2002-05-28
NO20022528L (no) 2002-05-28
WO2001040218A1 (fr) 2001-06-07
UY26456A1 (es) 2001-06-29
PL355667A1 (en) 2004-05-04
PE20010912A1 (es) 2001-09-01
CZ20021849A3 (cs) 2002-08-14
PT1244650E (pt) 2003-11-28
EP1244650B1 (fr) 2003-06-25
ATE243692T1 (de) 2003-07-15
EA200200616A1 (ru) 2002-10-31
HUP0204429A2 (hu) 2003-04-28
AU2179001A (en) 2001-06-12
BR0015992A (pt) 2002-08-06
BG106753A (bg) 2003-02-28
MXPA02005276A (es) 2002-11-07
IL149402A0 (en) 2002-11-10
ES2202206T3 (es) 2004-04-01
DK1244650T3 (da) 2003-10-20
JP2003515604A (ja) 2003-05-07
DE60003583T2 (de) 2004-05-13
SK7402002A3 (en) 2002-11-06
CA2392507A1 (fr) 2001-06-07
DE60003583D1 (de) 2003-07-31
CO5251431A1 (es) 2003-02-28
EP1244650A1 (fr) 2002-10-02
YU38102A (sh) 2004-12-31

Similar Documents

Publication Publication Date Title
EE200200263A (et) Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid
ATE231872T1 (de) Thiazolopyrimidinderivate
MXPA03007140A (es) Derivados de carbolina.
ATE461217T1 (de) Glp-1-verbindungen
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE60216233D1 (en) Carbolinderivate
MXPA03002911A (es) Compuestos quimicos.
WO2002096903A3 (fr) Derives chimiques et leur application comme agent antitelomerase
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
MXPA02012659A (es) Derivados de pirazindiona condensados.
SE9904377D0 (sv) Pharmaceutical combinations
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
DE60112960D1 (de) Kondensierte pyridoindolderivate
SE0301654D0 (sv) Novel compounds
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
MXPA02012472A (es) Compuestos quimicos.
DE60213798D1 (de) Carbolinderivate als pdev inhibitoren
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
NO20005548L (no) Mykobakterieinhibitorer
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.